The Canadian Interventional Radiology Association (CIRA) Board of Directors has announced the appointment of Daniel Lapointe as CIRA’s new executive director on the association’s website.
Two new sub-analyses from the IN.PACT Global Study of the IN.PACT Admiral in patients with peripheral artery disease have been reported at the annual 2017 Charing Cross Symposium (CX) in London, UK, one of the world’s largest educational meetings specialising in vascular and endovascular disease management.
Positive results from the RANGER SFA trial for Boston Scientific’s Ranger paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter have been presented at the 2017 CX Symposium in London, UK. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularisation at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
BD (Becton, Dickinson and company) has definitively agreed to acquire Bard for US$317 per common share in cash and stock, for a total consideration of US$24 billion.
Getinge is proud to announce the launch of the Advanta V12 32mm length balloon expandable covered stent at the Charing Cross International Conference. This is a much needed addition to the Advanta V12 product offering and will allow clinicians additional treatment options for optimal patient outcomes, a press release from the company says.
Merit has showcased a new radial compression product, Preludesync, on its website.
Lombard Medical’s portfolio of endovascular stent graft systems, Altura and Aorfix, were featured in scientific presentations at the 39th annual Charing Cross International Symposium (CX; 25–28 April, London, UK).
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and branched graft devices, based on a report of prospectively studied patients with complex aortic aneurysm in the May edition of the Journal of Vascular Surgery.
Howard Rosen has joined Intact Vascular’s executive management team as vice president of marketing and business development. In this position, Rosen will lead the company’s efforts to prepare for commercialisation of its Tack Endovascular System for the repair of dissections following peripheral artery angioplasty.
Contego Medical has announced that it has received CE mark for its Vanguard IEP peripheral balloon angioplasty system with integrated embolic protection. The company intends to launch the Vanguard IEP system in Europe to endovascular specialists performing lower limb angioplasty procedures.
Twelve posters selected for presentation out of 68 posters displayed were carefully reviewed by the CX Abstract Board, who decided to award their prize of a free CX 2018 registration to (San Donato Milanese, Italy) for her poster, “Study and patient specific prediction of the fatigue behaviour of peripheral nitinol stent of the superficial femoral arteries through mathematical modelling”. One of four peripheral arterial posters, Mazzaccaro’s took an innovative approach to the subject at hand.
The CX Venous Workshop returned on Wednesday, bigger than ever before. With a new location in the Exhibition Hall and its own series of edited live case presentations, it continues to showcase innovative venous technology and offer delegates the chance to get hands-on with the latest advances in the arena. Expanding from previous years’ Venous Village to this year’s Venous City, the workshop has brought together delegates and demonstrators from all over the world to experience the state of the art.
For the first time, Day One of this year’s CX Venous Workshop included two edited case presentations (CX Venous Edited Cases). The standing-room only session gave delegates the opportunity to watch two innovative devices in action and quiz experienced surgeons on their top procedural tips.
First-time data presentation from the SWAN (Screening Women for Abdominal aNeurysms) project was heard at the 2017 Charing Cross Symposium (CX; 25–28 April, London, UK). The study, which used simulation to evaluate whether inviting women to be screened for abdominal aortic aneurysm would have clinical benefit, or be cost-effective, revealed that such a programme would yield a very small benefit. Further, such a screening programme would not be cost-effective in the UK context.
A “podium first” presentation of very long-term follow-up data from the EVAR 2 trials suggests that endovascular aneurysm repair (EVAR) fails to improve all-cause mortality, but reduces aneurysm-related mortality compared to no treatment in abdominal aortic aneurysm patients who are physically ineligible for open repair. The data were presented yesterday at CX and prompted a discussion on the dilemma of whether to offer, or withhold, EVAR in this group of frail patients in the light of these findings. The panel discussion then prompted a spontaneous show of hands in which delegates backed the idea of adopting a model of shared decision-making with frail patients who are in poor health when discussing EVAR or no treatment.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos